Department of Applied Health Science, School of Public Health, Indiana University, Bloomington, IN, United States of America.
Department of Applied Health Science, School of Public Health, Indiana University, Bloomington, IN, United States of America.
Prev Med. 2022 Aug;161:107116. doi: 10.1016/j.ypmed.2022.107116. Epub 2022 Jun 21.
Unnecessary/unsafe opioid prescribing has become a major public health concern in the U.S. Statewide prescription drug monitoring programs (PDMPs) with varying characteristics have been implemented to improve safe prescribing practice. Yet, no studies have comprehensively evaluated the effectiveness of PDMP characteristics in reducing opioid-related potentially inappropriate prescribing (PIP) practices. The objective of the study is to apply machine learning methods to evaluate PDMP effectiveness by examining how different PDMP characteristics are associated with opioid-related PIPs for non-cancer chronic pain (NCCP) treatment. This was a retrospective observational study that included 802,926 adult patients who were diagnosed NCCP, obtained opioid prescriptions, and were continuously enrolled in plans of a major U.S. insurer for over a year. Four outcomes of opioid-related PIP practices, including dosage ≥50 MME/day and ≥90 MME/day, days supply ≥7 days, and benzodiazepine-opioid co-prescription were examined. Machine learning models were applied, including logistic regression, least absolute shrinkage and selection operation regression, classification and regression trees, random forests, and gradient boost modeling (GBM). The SHapley Additive exPlanations (SHAP) method was applied to interpret model results. The results show that among 1,886,146 NCCP opioid-related claims, 22.8% had an opioid dosage ≥50 MME/day and 8.9% ≥90 MME/day, 70.3% had days supply ≥7 days, and 10.3% were when benzodiazepine was filled ≤7 days ago. GBM had superior model performance. We identified the most salient PDMP characteristics that predict opioid-related PIPs (e.g., broader access to patient prescription history, monitoring Schedule IV controlled substances), which could be informative to the states considering the redesign of PDMPs.
在美国,不必要/不安全的阿片类药物处方已成为一个主要的公共卫生关注点。为了改善安全处方实践,已经实施了具有不同特征的全州范围的处方药物监测计划(PDMP)。然而,目前还没有研究全面评估 PDMP 特征在减少阿片类药物相关潜在不适当处方(PIP)实践方面的有效性。本研究的目的是应用机器学习方法通过检查不同 PDMP 特征与非癌症慢性疼痛(NCCP)治疗相关的阿片类药物 PIP 的关联来评估 PDMP 的有效性。这是一项回顾性观察性研究,共纳入 802926 名成年患者,这些患者被诊断为 NCCP,获得阿片类药物处方,并在一家美国主要保险公司的计划中持续参保超过一年。研究考察了四种阿片类药物相关 PIP 实践的结果,包括剂量≥50 MME/天和≥90 MME/天、供应天数≥7 天和苯二氮䓬类药物-阿片类药物共同处方。应用了机器学习模型,包括逻辑回归、最小绝对收缩和选择操作回归、分类和回归树、随机森林和梯度提升建模(GBM)。应用了 SHapley Additive exPlanations(SHAP)方法来解释模型结果。结果显示,在 1886146 例 NCCP 阿片类药物相关索赔中,22.8%的患者阿片类药物剂量≥50 MME/天,8.9%的患者阿片类药物剂量≥90 MME/天,70.3%的患者供应天数≥7 天,10.3%的患者苯二氮䓬类药物处方≤7 天前开具。GBM 具有卓越的模型性能。我们确定了预测阿片类药物相关 PIP 的最显著 PDMP 特征(例如,更广泛地获取患者处方历史记录,监测附表 IV 受控物质),这可能为考虑重新设计 PDMP 的各州提供信息。